Antidiabetic Pharmacology Part 3: Insulin

This comprehensive CE activity focuses on the critical aspects of insulin pharmacotherapy in the management of diabetes mellitus. As the prevalence of diabetes continues to rise globally, understanding the pharmacological landscape is crucial for healthcare professionals involved in patient care. The course begins with an overview of diabetes epidemiology, risk factors, and the diagnostic criteria for diabetes and prediabetes. It then transitions into the classification and clinical use of various types of insulin, detailing their mechanisms of action, dosing strategies, side effects, and contraindications. Special attention is given to individualizing insulin regimens, insulin titration, and the management of hypoglycemia. Healthcare providers will gain essential insights into initiating and adjusting insulin therapy to optimize glycemic control and reduce the risk of diabetes-related complications. The content is evidence-based and adheres to the latest treatment guidelines, equipping learners with practical tools to enhance therapeutic outcomes and support patient-centered diabetes management.

Educational Objectives

• Identify the global and national prevalence, as well as key risk factors associated with diabetes mellitus and prediabetes.
• Describe the current guidelines for diabetes mellitus classification, screening protocols, and diagnostic thresholds.
• Explain the pharmacodynamics and pharmacokinetics of different insulin types, including rapid-acting, short-acting, intermediate-acting, and long-acting formulations.
• Recognize the clinical indications, dosing protocols, and contraindications for insulin therapy in the treatment of diabetes mellitus.
• Evaluate common side effects of insulin use, particularly hypoglycemia, and outline appropriate monitoring and management strategies.

Who Should Do This Course

This course is designed for Physicians, Registered Nurses (RNs), Nurse Practitioners (NPs), and Physician Assistants (PAs) practicing in the fields of Family Medicine, Internal Medicine, General Practice, Primary Care, Endocrinology, and Pharmacology. It is particularly beneficial for professionals involved in managing patients with diabetes, as well as those responsible for prescribing and adjusting insulin therapies.

Did You Know?

• According to the CDC, over 38 million people in the U.S. have diabetes, with approximately 1 in 5 unaware of their condition (CDC, 2023).
• Insulin therapy is essential for all patients with Type 1 diabetes and many with advanced Type 2 diabetes (American Diabetes Association, 2024).
• Proper insulin use can reduce A1C levels by an average of 1.5–3.5%, significantly decreasing the risk of complications (UpToDate, 2024).
• Hypoglycemia is the most common side effect of insulin therapy, with severe episodes resulting in over 100,000 ER visits in the U.S. annually (NIH, 2022).
• Newer ultra-long-acting insulins like degludec offer more flexible dosing and reduced hypoglycemia risk in clinical trials (Lancet Diabetes Endocrinol, 2023).